MUNICH—The role of poly ADP ribose polymerase (PARP) inhibitors for treating newly diagnosed advanced ovarian cancer was under review at the 2018 annual congress of the European Society for Medical Oncology (ESMO) in the light of findings from the SOLO1 randomized phase three trial in which there was more than a doubling of the numbers of patients surviving three years without disease recurrence in patients with BRCA gene mutations who were treated with olaparib after initial chemotherapy compared with similar patients receiving a placebo.
http://212.114.167.162/slidecenter/esmo2018/attendee/confcal/session/calendar?q=LBA7_PR
Unique
Commenting on the findings Jonathan Ledermann MD FRCP Professor of Medical Oncology, Director of the UCL Cancer Trials Centre and Clinical Director at the UCL Cancer Institute in University College London said the study had been a first. “We know that olaparib and other PARP inhibitors are very successful in delaying disease progression in patients with recurrent disease. But this trial tested maintenance olaparib in the front-line setting after surgery and chemotherapy—and that was unique,” he tells the Audio Journal of Oncology.